NICE 2026: The goalposts have moved

Three to six months. That is the time saving the new NICE–MHRA Aligned Pathway delivers for pharmaceutical companies navigating UK market access. For an oncology asset with a narrowing patent window, that is commercially significant. For a patient with a life-limiting condition, it can be clinically significant. The announcement, made formally at the NICE Annual Conference in Manchester on 17 March 2026, was the headline, but it was not the whole story.

Under new chief executive Prof Jonathan Benger, who took the role in December 2025, NICE used the conference to signal a redesign of the HTA operating model in England. The aligned pathway, a whole lifecycle approach to guidance, an imminent cost-effectiveness threshold increase, and a structural push to put health technology on equal footing with medicines: each of these matters individually. Together, they constitute a material shift in how pharmaceutical companies must plan for UK market access.

1. The aligned pathway eliminates the most expensive inefficiency in UK market access

Benger framed the problem directly: historically, companies aimed for the MHRA goalposts and found NICE’s were somewhere else. Misalignment between the two bodies has been the single largest source of wasted investment and delayed access. A company could collect the right data to satisfy the regulator and discover at submission stage that the HTA body needed different endpoints, different comparators, different follow-up. The aligned pathway closes that gap.

Equally significant is the launch of Joint Scientific Advice, aligned guidance from both MHRA and NICE, available early in development. MHRA chief executive Lawrence Tallon used the exam analogy: you need to know the exam question before you sit the paper, and crucially, that the question is the same for both examiners. The commercial implication is direct. Companies that engage early will design development programmes with confidence that evidence standards hold for both regulatory and reimbursement decisions. Those that do not will continue to discover the misalignment at submission stage, when it costs most to fix.

2. Whole lifecycle assessment transforms post-approval commercial strategy

NICE’s second major ambition is a shift from point-in-time assessment to continuous pathway evaluation. As patents expire and real-world evidence accumulates, NICE will re-evaluate treatments, reassigning them within pathways, expanding eligible populations, and sequencing them against newer entrants. Abiraterone for prostate cancer is the worked example: negative guidance in 2012 with positive recommendation in later lines, re-evaluated post-patent expiry, now available to thousands more patients. Bevacizumab for colorectal cancer follows the same logic.

The NHS has already saved more than £1.2 billion from biosimilars in the last three years, with a further £1 billion targeted from five biosimilars over the next three. That savings agenda is the explicit mechanism for creating financial headroom to fund new innovations, and it accelerates under a whole lifecycle model.

For originator companies, commercial strategy can no longer be designed around a single HTA decision. Post-launch real-world evidence, pathway positioning, and competitor biosimilar dynamics become active strategic variables from launch day. By 2028, NICE intends a single unified topic selection and prioritisation process across medicines, health technologies, and clinical guidelines. Companies currently navigating three separate processes need to plan for that integration now.

3. The cost-effectiveness threshold is moving—this year

Benger confirmed the Government intends to increase the cost-effectiveness threshold, that NICE has consulted and published its plans, and that it is ready to implement “without hesitation and without delay” on direction. A new value set consultation is due from April, updating the quality-of-life assessment framework to better reflect societal preferences.

The threshold increase will bring previously rejected medicines into scope. For companies with products that failed appraisal at the existing threshold, this is a direct resubmission opportunity, conditional on presentation of new substantial evidence. For companies in active development, it shifts the evidence-versus-price-negotiation trade-off. This is not a distant policy consideration, it is an active variable in 2026 launch planning.

4. Health tech has a pathway, but budget architecture remains the blocker

The National Health Tech Access Programme gives health technology the legal standing that medicines have always held. Two topics have already entered the technology appraisal process via ministerial referral. Standardised value-based procurement guidance follows in June; an innovation passport comparison tool by December.

But the session on health tech was the most uncomfortable of the day. Prof Rick Body quantified the cost of system fragmentation: the RCEM analysis indicates 16,644 estimated excess deaths from emergency department crowding in 2024 alone. Point-of-care troponin testing could reduce that number, but the emergency department pays for the test while the savings accrue in ambulances. No credible solution to that budget silo problem was offered, because none sits within NICE’s gift.

Dr Leila Shepherd from the Helix Centre identified a compounding problem: a NICE assessment operates to different evidence standards from a local NHS business case, which differs again from an academic health economics evaluation. For companies developing digital health or AI-assisted clinical tools, that incoherence adds cost and uncertainty to every market entry. The MHRA’s AI in Healthcare Commission will be published in 2026, its three signals are worth noting now

appropriate weight on the risk of inaction, not just action
emphasis shifting from pre-market approval to post-market surveillance
contextualised evaluation of AI within deployment settings. For AI-enabled pharma and medtech, this is the framework that will govern their route to market

5. GLP-1s have exposed a commissioning failure that will recur

The prevention session was the most candid of the conference. Prof Ewan Maule described GLP-1 receptor agonist introduction as “the most challenging new drug introduction the NHS has probably ever seen”—driven by celebrity demand, illicit markets, and a two-tier private/NHS system producing inequitable access. Sarah Le Brocq stated that the NHS waiting list for some obesity medications stands at 12 years. No other therapy area would tolerate this.

The structural cause is not clinical. NICE approval does not create NHS readiness. Pathway capacity, workforce capability, and follow-on behavioural support all sit outside NICE’s remit. For pharmaceutical companies with obesity pipeline assets, this is a direct post-launch risk. The failure mode is predictable: NICE recommends, commissioning stalls, patients wait, reputational damage accumulates. Engagement with ICBs on pathway design—not just reimbursement—is the necessary complement to any NICE approval, and it needs to begin before submission.

6. ICB-level intelligence is now a commercial priority

Kelly Broad, Deputy Chief Pharmacist at Cambridgeshire and Peterborough ICB, demonstrated what effective commissioning analysis looks like for the anticipated dupilumab COPD recommendation. Her top 5% of COPD patients, 686 people across roughly 10 GP practices, account for £422,000 in primary care medicines spend and £6.4 million in emergency admissions annually. Those practices are concentrated in the most deprived areas of the patch.

That level of granularity, patient segments, cost burden, geography, deprivation, is what ICBs need to redesign pathways rather than simply add new treatments to existing ones. Companies that can provide this analysis will accelerate adoption. Companies that arrive with a national product story and no local data will wait.

What pharma needs to do—and when

Six implications follow directly from what NICE announced:

Be ready to move in 3–6 months, not 12

The aligned pathway only creates value if the company is operationally ready to launch the moment approval lands. Pricing position, NHS contracting infrastructure, and evidence packages must be built in parallel with the regulatory process, not after it. Joint Scientific Advice makes that possible, it allows companies to align their development programme to both MHRA and NICE evidence standards simultaneously, eliminating the rework that currently consumes months of post-approval time. Companies that treat NICE submission as the start of commercial preparation will lose the time saving the pathway is designed to deliver.

Build the payer value case for NHS England negotiations—with MFN in mind

The commercial negotiation with NHS England that follows NICE approval now carries global consequences. Most Favoured Nation pricing dynamics mean the price agreed in England functions as a reference floor for other markets. The health economic and real-world evidence package presented in that negotiation needs to be built to that standard, not constructed to clear the appraisal threshold and then retrofitted. Companies that arrive at commercial negotiation with thin outcome data and broad population estimates will be negotiating from weakness. Those with granular, NHS-specific evidence of cost offset, pathway impact, and patient-level outcomes will not.

Build the prevention business case before someone else does.

The GLP-1 debacle is a warning, not an isolated failure. NHS England projects it could take up to 12 years to extend tirzepatide access to the entire eligible population. This is not a supply problem, it is a commissioning architecture problem, compounded by the absence of a credible economic case for prevention at system level. For any asset with a prevention or early intervention dimension, the business case needs to be built proactively: what is the downstream HCRU cost of untreated patients, what does earlier intervention save the system, and who in the NHS bears the cost today versus who would benefit from treatment? Without that analysis, ICBs default to managing today’s budget rather than investing in tomorrow’s avoided cost. The company that provides it shapes the commissioning conversation. The company that waits inherits a 12-year queue.

Plan ICB-level uptake before approval, not after

NICE approval is the starting gun, not the finish line. Broad’s data from Cambridgeshire and Peterborough made the point precisely. The top 5% of COPD patients in her ICB, 686 people across 10 GP practices, account for £9,330 each in emergency admission costs annually. Those patients are clustered in the most deprived practices in the north of the patch. A national product story does not commission a pathway for that population. An ICB needs to know which patients, where, at what cost to the system, with what prescribing history, and how their condition has progressed, before it can redesign a pathway rather than simply add a treatment to a formulary.

Use data, digital and AI to turn guidelines into practice

Benger’s whole lifecycle ambition, dynamic guidelines that update as evidence evolves, only delivers if the NHS can act on them at the point of care. That requires computable evidence: guideline recommendations translated into data-driven decision support tools that identify which patients should be on which treatment, flag those who are not, and track whether clinical practice is changing. A NICE recommendation embedded in a clinical decision support tool that fires at the point of prescribing is worth more than a recommendation that sits in a PDF. Companies that invest in this layer, working with NHS systems to make guideline-directed therapy computable and actionable, will see faster uptake and generate the real-world outcomes data that sustains their position through whole lifecycle review.

Rethink who you are selling to, and with what

The NICE appraisal is one gate. But the levers that actually determine whether a medicine reaches patients are far wider: NICE clinical guidelines, not just technology appraisals; local formulary decisions at ICB and primary care network level; financial incentives such as QOF indicators and Directed Enhanced Services that make prescribing behaviourally rewarding for GPs; digital infrastructure that embeds treatment recommendations at the point of care; and outcome-based contracting models that give NHS commissioners confidence in the investment. The value proposition needs to be constructed for each of these audiences, NHS England, ICBs, primary care, public health, local government where prevention budgets sit, not just for the NICE committee. Companies that arrive with a single clinical evidence dossier and expect the system to do the rest have misread how the NHS actually decides to change practice.

Every one of these actions requires the same thing: linked, patient-level NHS data on cost, utilisation, prescribing, and geography — and the analytical infrastructure to turn it into an ICB-ready business case before approval lands.

CF’s HealthStrata® platform provides the analytical foundation across all six. For any cohort defined by condition, demographics, geography, or deprivation, HealthStrata® sets individual and population-level healthcare resource use alongside prescribing patterns and costs, and tracks how both evolve over time. It quantifies the downstream cost of inaction, the prevention business case, and identifies where high-cost patients are concentrated, as Broad’s £9,330 per-patient emergency admission figure illustrates. It maps prescribing dynamics to show where treatment gaps persist and how fast they are closing. And it provides the patient identification layer needed to make guideline-directed therapy computable in practice. That evidence base spans every lever: ICB business case, NHS England commercial negotiation, prevention investment case, guideline-embedded decision support, and outcomes tracking for value-based contracting.

Access is the beginning. Uptake is the work.

CF attended the NICE Annual Conference on 17 March 2026. For further information on how CF can support your access, evidence, or commercial strategy, contact our Life Sciences practice.

byhContact us today

NICE 2026: The goalposts have moved